Autonomix Medical, Inc. (AMIX) Cash Flow Statement
Where AMIX’s cash came from and went, FY2026
March 31, 2026 · U.S. dollars- Cash from operations
- −$12.3M
- Capital expenditures
- $10,000
- Free cash flow
- −$12.3M
- Returned to shareholders
- —
- Change in cash
- −$2.1M cash at year-end $7.0M
Drawn to scale: where the cash came from and how it was used. Hover for values.
AMIX operating cash flow, capex and free cash flow
AMIX cash flow trends, FY2022–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$387,307FY2022 | −$12.3MFY2026 | — | |
| Capital expenditures | $3FY2022 | $10,000FY2026 | +659.8%/yr | |
| Free cash flow | −$387,310FY2022 | −$12.3MFY2026 | — | |
| Stock-based compensation | $300FY2022 | $529,000FY2026 | +548.1%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AMIX cash flow by activity
AMIX net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
AMIX cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$16.7M | −$11.4M | −$15.4M | −$2.0M | −$13.3M |
| Depreciation & amortization | $12,000 | $183,000 | $81,000 | $0 | — |
| Stock-based compensation | $529,000 | $1.6M | $618 | $0 | $300 |
| Change in working capital | −$107,000 | $1.2M | $79,000 | $136,079 | $204,414 |
| Other non-cash items | $4.0M | $101,000 | $8.6M | $0 | $12.7M |
| Cash from operating activities | −$12.3M | −$8.3M | −$6.6M | −$1.9M | −$387,307 |
| Investing activities | |||||
| Capital expenditures | −$10,000 | −$14,000 | −$19,000 | −$2 | −$3 |
| Investments (net) | — | −$14,000 | −$19,000 | $0 | — |
| Acquisitions & other investing | $0 | $14,000 | $19,000 | — | — |
| Cash from investing activities | −$10,000 | −$14,000 | −$19,000 | — | — |
| Financing activities | |||||
| Net borrowing (repayment) | — | $0 | $2.0M | $0 | — |
| Shares issued | $3.5M | $10.0M | $13.7M | $675,000 | $0 |
| Other financing | $6.6M | −$1.2M | −$1.3M | $0 | $2.4M |
| Cash from financing activities | $10.2M | $8.8M | $14.4M | $675,000 | $2.4M |
| Summary | |||||
| Net change in cash | −$2.1M | $528,000 | $7.7M | −$1.2M | $2.0M |
| Cash at end of period | $7.0M | $9.1M | $8.6M | $864,618 | $2.0M |
| Free cash flow | −$12.3M | −$8.3M | −$6.7M | −$1.9M | −$387,310 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$2.7M | $1.4M | −$7.4M | −$3.3M | −$3.3M | −$3.2M | −$2.7M | −$2.8M | −$2.7M | −$3.1M | −$3.1M | −$6.0M |
| Depreciation & amortization | $3,000 | $3,000 | $4,000 | $2,000 | $3,000 | $48,000 | $47,000 | $45,000 | $43,000 | $46,000 | $35,000 | $0 |
| Stock-based compensation | $2,000 | −$137,000 | $140,000 | $405,000 | $388,000 | $405,000 | $418,000 | $445,000 | $360,000 | $255,000 | $200,000 | $151,000 |
| Change in working capital | −$821,000 | −$230,000 | $286,000 | $342,000 | $342,000 | $229,000 | −$53,000 | $620,000 | $444,000 | $130,467 | −$128,000 | −$51,000 |
| Other non-cash items | $0 | −$4.0M | $4.0M | −$80,000 | $0 | $0 | $0 | $101,000 | $0 | $124,829 | $450,000 | $4.8M |
| Cash from operating activities | −$3.5M | −$2.9M | −$3.0M | −$2.7M | −$2.6M | −$2.5M | −$2.3M | −$1.6M | −$1.9M | −$2.6M | −$2.6M | −$1.1M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$3,000 | −$7,000 | $0 | $0 | −$4,000 | −$5,000 | $0 | −$5,000 | −$15,996 | −$16,000 | $0 |
| Investments (net) | — | — | — | $0 | $0 | −$4,000 | −$5,000 | $0 | −$5,000 | −$3,000 | −$16,000 | $0 |
| Acquisitions & other investing | — | $0 | $0 | — | — | $4,000 | $5,000 | — | $5,000 | $2,996 | $16,000 | — |
| Cash from investing activities | — | −$3,000 | −$7,000 | — | — | −$4,000 | −$5,000 | — | −$5,000 | −$16,000 | −$16,000 | — |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | — | — | — | — | — | $0 | $0 | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $2.1M | $2,000 | $10.0M | $0 | $0 | $10.9M | $0 | $0 |
| Other financing | $0 | −$35,000 | $5.4M | $2.1M | −$64,000 | −$176,000 | −$1.1M | $0 | $0 | −$9.2M | $1.6M | $350,000 |
| Cash from financing activities | $0 | −$35,000 | $5.4M | $2.1M | $2.1M | −$174,000 | $9.0M | $0 | $0 | $1.6M | $1.6M | $350,000 |
| Summary | ||||||||||||
| Net change in cash | −$3.5M | −$2.9M | $2.5M | −$547,000 | −$547,000 | −$2.7M | $6.7M | −$1.6M | −$1.9M | −$927,322 | −$927,000 | −$794,000 |
| Cash at end of period | $3.5M | $7.0M | $9.9M | $8.6M | $8.6M | $9.1M | $11.8M | $5.2M | $6.8M | $1.2M | $1.2M | $2.1M |
| Free cash flow | −$3.5M | −$2.9M | −$3.0M | −$2.7M | −$2.6M | −$2.5M | −$2.3M | −$1.6M | −$1.9M | −$2.6M | −$2.6M | −$1.1M |
| Free cash flow margin | — | — | — | — | — | −2,922.1% | — | — | — | — | — | — |
| Capex / revenue | — | — | — | — | — | 4.7% | — | — | — | — | — | — |
| Operating cash flow / net income | — | −2.00 | — | — | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
AMIX cash generation
In fiscal 2026 (ended March 31, 2026), Autonomix Medical generated -$12.3 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$12.3 million. Cash and equivalents fell by $2.1 million over the year.
Related: AMIX income statement, AMIX balance sheet. See the AMIX stock overview for the latest quote and news.
AMIX cash flow FAQ
What is Autonomix Medical's free cash flow?
Autonomix Medical's free cash flow was -$12.3 million in fiscal 2026: -$12.3 million of operating cash flow minus $0.0 million of capital expenditures It was -$8.3 million a year earlier..
How much cash does Autonomix Medical generate from operations?
Autonomix Medical generated -$12.3 million of cash from operating activities in fiscal 2026.
How much does Autonomix Medical spend on capital expenditures?
Autonomix Medical spent $0.0 million on capital expenditures in fiscal 2026, compared with $0.0 million the year before.